KRTX

Karuna Therapeutics, Inc. (KRTX) | Rumor.io

Karuna Therapeutics

KRTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about KRTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Nov 10

Karuna Therapeutics (KRTX) has a promising drug candidate.
The company's valuation and potential deals are being discussed.
Karuna Therapeutics is mentioned as a potential takeover target.

Generated by AI

Sentiment

Of the messages about KRTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.98% -3.19
Bearish	—	—	—	14.02% +3.19

Bullish· Dec 22

Karuna Therapeutics' management is credited with timing the sale to Bristol Myers Squibb perfectly, achieving a 17x return from its IPO price.
The acquisition by Bristol Myers Squibb ensures that Karuna Therapeutics' muscarinic agonist (KarXT) will be brought to patients who need it quickly, without the need for a commercial team.
The deal is expected to generate significant revenue for Karuna Therapeutics, with projected peak revenue of $6.5 billion, and also provides a platform for future growth.

Bearish· Aug 8

Karuna Therapeutics, Inc. ($KRTX) is at risk of a significant price drop due to its overbought status and triple top formation.
The company's recent quarterly loss of $2.17 and upcoming offering may further exacerbate its financial struggles and lead to a decline in its stock price.
$KRTX's cash burn rate and delayed FDA submission timeline may ultimately lead to the company's inability to recover and sustain its current price levels.

Generated by AI

Topics

Of the messages about KRTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	89.74%
Controversies	—	—	—	3.97%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	6.29%

Analysts· Nov 18

Karuna Therapeutics, Inc. ($KRTX) received a price target raise to $109 from $35 at Goldman Sachs, with a Buy rating maintained.
Citi analyst Mohit Bansal raised the price target on $KRTX to $115, with a Buy rating, while Goldman Sachs analyst Salveen Richter also raised the price target to $109.
The positive price target changes were driven by the strong signal of efficacy and tolerability profile of KarXT in schizophrenia psychosis, with potential global peak sales of $1.9 billion and 60% probability of success.

Announcements· Dec 26

Karuna Therapeutics' schizophrenia treatment, KarXT, is the first new mechanism to tackle the disease in decades and is also being tested in psychosis due to Alzheimer's and other neuropsychiatric/neurodegenerative conditions.
Bristol Myers Squibb has committed $24B to business development deals in the second half of this year, following its $14B acquisition of Karuna Therapeutics.
Karuna Therapeutics' stock price surged over 45% on December 22, 2023, after Bristol Myers Squibb announced it would acquire the company for $14 billion in an all-cash deal.

Controversies· Dec 22

Law firms are investigating potential securities fraud claims against Karuna Therapeutics, Inc. ($KRTX) and its sale to Bristol Myers Squibb ($BMY).
Karuna Therapeutics ($KRTX) is being acquired by Bristol Myers Squibb ($BMY) in a $14 billion deal.
The proposed acquisition of Karuna Therapeutics ($KRTX) is being investigated by law firms for potential fairness to shareholders.

Technical Analysis· Nov 19

The 30-minute chart for $KRTX shows a potential short opportunity, with the 11am candle falling below 1030, but the 15-minute chart shows a high at 150.20, indicating a need to change time periods for a better entry.
A retest of $150.00 is possible, with a level 2 action showing 4400 shares at $123.75, indicating a good sign for day traders.
The neckline resistance at 136s is a key level to pay attention to, with a potential dip to 62 possible if the stock breaks below 124.

Generated by AI

Community

Of the messages about KRTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	59.75%
Newcomers	0%	0%	0%	40.25%

Regulars· Dec 22

Karuna Therapeutics, Inc. (KRTX) has been acquired by Bristol Myers Squibb Co. (BMY) in a deal valued at $14 billion, with KRTX shares trading up 48% in pre-market.
Regulars in the KRTX discussion highlight the persistence of Steve Paul, who was working on the KarXT predecessor in the 1990s, and the potential of Karuna's modulator of muscarinic receptors in its pipeline.
KRTX was not a clear shorting opportunity, and regulars express surprise that anyone would attempt to short the ticker, given the asset's recent acquisition and potential future revenue growth.

Newcomers· Dec 26

The newcomer users are primarily focused on the high price of Karuna Therapeutics ($KRTX) and the need for significant commercial spending and payer push to justify it.
The experimental schizophrenia treatment, KarXT, is seen as a significant asset in Karuna Therapeutics' pipeline, with potential applications in psychosis due to Alzheimer's and other neuropsychiatric/neurodegenerative disorders.
The acquisition of Karuna Therapeutics by Bristol Myers Squibb ($BMY) is viewed as a strategic match, given Bristol's focus on neurodegeneration and neuroinflammation, and Karuna's psychology-centric approach to neurological diseases.

Generated by AI

Also Discussed

Investors talking about KRTX also mention

#	Name	Attention
1	ITCI - Intra-Cellular Therapies, Inc.	——
2	Axsome Therapeutics IncAXSM	0.01%0
3	MYOV - Myovant Sciences Ltd.	——
4	AGRX - Agile Therapeutics, Inc.	——
5	NGM - NGM Biopharmaceuticals, Inc.	——
6	MRTX - Mirati Therapeutics, Inc.	——
7	Denali Therapeutics Inc.DNLI	0%new
8	SAGE - Sage Therapeutics, Inc.	——
9	Alector Inc.ALEC	0%new
10	Neurocrine Biosciences, Inc.NBIX	0%new